category,datetime,headline,id,image,related,source,summary,url
company,1769018787,"Final Trade: BMY, IGV, SOXX, GEN, AMZN",138205234,https://image.cnbcfm.com/api/v1/image/108255406-17690366381769036636-43616478975-1080pnbcnews.jpg?v=1769036637&w=1920&h=1080,BMY,CNBC,The final trades of the day with CNBC's Melissa Lee and the 'Fast Money' traders.,https://finnhub.io/api/news?id=c71d27c6932159b148d0f0ce97b4aaeb9312a9e4f9817c87e1505be5380ad2d2
company,1769015100,"The Best Stocks to Invest $1,000 in Right Now",138197282,https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png,BMY,Yahoo,"Large, well-run dividend-paying companies with attractive yields are out there if you look hard enough.",https://finnhub.io/api/news?id=7cebd078bec92cf205f90ef194de7f12f32802c70e70c2cd0ec8e131a93c0612
company,1768997457,Leerink Bullish on Bristol-Myers Squibb Company (BMY) Amid Ample Pipeline Optionality in 2026,138195195,https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png,BMY,Yahoo,"Bristol-Myers Squibb Company (NYSE:BMY) is one of the best undervalued wide moat stocks. On January 13, 2026, Leerink raised its price target on Bristol-Myers Squibb Company (NYSE:BMY) from $54.00 to $60.00, while reiterating an ‘Outperform’ rating. Highlighting ample pipeline optionality in 2026, the firm noted 12 registration data readouts across eight assets. Most of these […]",https://finnhub.io/api/news?id=80cb26175b05e83dad658269310281d2a01b9ebf4b10ba979f6058468ae696b6
company,1768996822,"Bristol-Myers Squibb Company's (NYSE:BMY) recent 3.0% pullback adds to one-year year losses, institutional owners may take drastic measures",138195196,https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png,BMY,Yahoo,Key Insights Significantly high institutional ownership implies Bristol-Myers Squibb's stock price is sensitive to...,https://finnhub.io/api/news?id=b209295f5615039b592912f43c17573faa6aa8f0a5ceb0bb3c68aa1cbc44930b
company,1768996800,"The T1D Fund Strengthens Expertise With Appointment of Biotech Industry Veteran and Cell Therapy Expert Teresa Foy, Ph.D., to Advance Next Generation of Type 1 Diabetes (""T1D"") Therapies",138195197,https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png,BMY,Yahoo,"The T1D Fund: A Breakthrough T1D Venture, LLC, an impact investment fund focused on accelerating life-changing solutions to treat, prevent, and ultimately cure type 1 diabetes, today announced Teresa Foy, Ph.D., has joined the Fund as a strategic consultant.",https://finnhub.io/api/news?id=73b66825b942646c72a0a51171c1eef187cb45457cf869079b4a4efc2d28796c
company,1768961495,AI Partnerships Across Healthcare and Retail Could Be A Game Changer For Microsoft (MSFT),138192063,https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png,BMY,Yahoo,"In January 2026, Bristol Myers Squibb, Algolia, Hanshow, PayPal, Fiserv and others announced new collaborations with Microsoft to deploy AI across healthcare imaging, retail commerce, store operations, payments and financial services, deepening adoption of Azure, Copilot and the Precision Imaging Network. These agreements highlight how Microsoft’s AI and cloud platforms are becoming embedded in mission‑critical workflows, from early lung cancer detection to “agentic” shopping and store...",https://finnhub.io/api/news?id=abbf70d3833134fdaba66b089eaac4005cb4d34835c3c6dec8c9b0cc1bbf05fc
company,1768959001,CNBC's UK Exchange newsletter: A diplomacy tightrope for Britain’s Starmer after Trump’s tirades,138196914,https://image.cnbcfm.com/api/v1/image/108254684-1768965252681-gettyimages-2240467882-AFP_78MT3V6.jpeg?v=1768965270&w=1920&h=1080,BMY,CNBC,U.K. PM Keir Starmer is treading a fine line in diplomacy — and appears to be banking on Britain’s “special relationship” with the U.S. to deliver a compromise.,https://finnhub.io/api/news?id=37a8552d591771a5b80abd1ed556a432a90c2a3cb81c0ae6e176e1586e6aa1ad
